BRII-835 (VIR-2218)

DRUG3 trials

Sponsors

Brii Biosciences Limited

Conditions

Chronic Hepatitis B Virus (HBV) InfectionFor Treatment of Chronic Hepatitis B Virus InfectionHepatitis B, Chronic

Phase 2

Study to Investigate the Safety and Efficacy of BRII-835 and BRII-179 Combination Therapy Treating Chronic Hepatitis B Virus (HBV) Infection

CompletedNCT04749368

Brii Biosciences LimitedHepatitis B, Chronic

Start: 2021-04-12End: 2023-07-04Updated: 2024-06-18

Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH)

Active, not recruitingNCT06491563

Brii Biosciences LimitedFor Treatment of Chronic Hepatitis B Virus Infection

Start: 2024-08-06End: 2027-06-30Target: 150Updated: 2024-12-30

A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNα in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE)

RecruitingNCT06650852

Brii Biosciences LimitedChronic Hepatitis B Virus (HBV) Infection

Start: 2024-10-31End: 2027-07-31Target: 250Updated: 2025-05-23

Related Papers

The Impact of Hepatitis B Surface Antigen Reduction via Small Interfering RNA Treatment on Natural and Vaccine (BRII-179)-Induced Hepatitis B Virus-Specific Humoral and Cellular Immune Responses.

2025-03-035 citations

Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib/IIa study.

2021-09-0837 citations